Analysts Set Expectations for BOLT Q1 Earnings

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Bolt Biotherapeutics in a report released on Tuesday, March 25th. HC Wainwright analyst E. White expects that the company will post earnings of ($0.33) per share for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Bolt Biotherapeutics’ Q2 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.32) EPS, FY2026 earnings at ($0.56) EPS and FY2027 earnings at ($0.34) EPS.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Monday, March 24th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.38). Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.79 million.

Separately, Stifel Nicolaus decreased their price objective on shares of Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating for the company in a research note on Tuesday. Five analysts have rated the stock with a hold rating, According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $1.13.

Bolt Biotherapeutics Price Performance

BOLT stock opened at $0.44 on Friday. The firm has a 50-day moving average of $0.47 and a two-hundred day moving average of $0.55. The firm has a market capitalization of $16.82 million, a PE ratio of -0.26 and a beta of 0.94. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21. Bolt Biotherapeutics has a one year low of $0.38 and a one year high of $1.56.

Institutional Trading of Bolt Biotherapeutics

Several hedge funds and other institutional investors have recently modified their holdings of BOLT. Millennium Management LLC acquired a new position in Bolt Biotherapeutics in the 4th quarter worth about $25,000. Squarepoint Ops LLC bought a new stake in shares of Bolt Biotherapeutics during the 4th quarter worth about $26,000. Velan Capital Investment Management LP acquired a new position in shares of Bolt Biotherapeutics during the 4th quarter valued at about $27,000. Citadel Advisors LLC bought a new position in shares of Bolt Biotherapeutics in the 4th quarter valued at approximately $42,000. Finally, FMR LLC raised its stake in shares of Bolt Biotherapeutics by 33.2% in the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after acquiring an additional 28,773 shares in the last quarter. 86.70% of the stock is currently owned by hedge funds and other institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.